144 related articles for article (PubMed ID: 19343481)
21. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
Case AS; Rocconi RP; Kilgore LC; Barnes MN
Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
[TBL] [Abstract][Full Text] [Related]
22. Once-weekly dose of epoetinum alfa in cancer patients with anemia receiving radiotherapy.
Ots PM; Pérez AR; Carrizosa CL; Ocaña CV; de Dios Sáez Garrido J; Delgado Pérez JM
Clin Transl Oncol; 2005 Dec; 7(11):486-92. PubMed ID: 16373059
[TBL] [Abstract][Full Text] [Related]
23. A prospective cohort study on the impact of darbepoetin alfa on quality of life in daily practice following anemia treatment guideline revisions.
Steinmetz T; Kindler M; Lange O; Vehling-Kaiser U; Kuhn A; Hellebrand E
Curr Med Res Opin; 2014 Sep; 30(9):1813-20. PubMed ID: 24849527
[TBL] [Abstract][Full Text] [Related]
24. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy.
Dangsuwan P; Manchana T
Gynecol Oncol; 2010 Mar; 116(3):522-5. PubMed ID: 20051288
[TBL] [Abstract][Full Text] [Related]
25. Hemoglobin decline in chemotherapy patients prior to and after policy changes affecting use of erythropoiesis-stimulating agents: 2006-2009.
Hill JW; Cong Z; Hess G; McGarvey N; Nordyke RJ
J Int Med Res; 2012; 40(4):1532-45. PubMed ID: 22971506
[TBL] [Abstract][Full Text] [Related]
26. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy.
Ludwig H; Sundal E; Pecherstorfer M; Leitgeb C; Bauernhofer T; Beinhauer A; Samonigg H; Kappeler AW; Fritz E
Cancer; 1995 Dec; 76(11):2319-29. PubMed ID: 8635038
[TBL] [Abstract][Full Text] [Related]
27. Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey.
Repetto L;
Crit Rev Oncol Hematol; 2009 Nov; 72(2):170-9. PubMed ID: 19406660
[TBL] [Abstract][Full Text] [Related]
28. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.
Cartenì G; Giannetta L; Ucci G; De Signoribus G; Vecchione A; Pinotti G; Puglisi F; Contillo A; Pezzella G; Orecchia S; Beccaglia P;
Support Care Cancer; 2007 Sep; 15(9):1057-66. PubMed ID: 17431689
[TBL] [Abstract][Full Text] [Related]
29. The impact of recently published negative erythropoiesis-stimulating agent studies on the clinical management of cancer-related anemia at a single center.
Abdel-Razeq H; Hijjawi S; Abdulelah H; Amarin R; Asawaeer M; Shaheen H
Hematol Oncol Stem Cell Ther; 2010; 3(2):78-83. PubMed ID: 20543541
[TBL] [Abstract][Full Text] [Related]
30. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy.
Shasha D; George MJ; Harrison LB
Cancer; 2003 Sep; 98(5):1072-9. PubMed ID: 12942577
[TBL] [Abstract][Full Text] [Related]
31. Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapy.
Hinds PS; Hockenberry M; Feusner J; Hord JD; Rackoff W; Rozzouk BI
J Support Oncol; 2005; 3(6 Suppl 4):10-1. PubMed ID: 16355549
[No Abstract] [Full Text] [Related]
32. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
Charu V; Saidman B; Ben-Jacob A; Justice GR; Maniam AS; Tomita D; Rossi G; Rearden T; Glaspy J
Oncologist; 2007 Oct; 12(10):1253-63. PubMed ID: 17962619
[TBL] [Abstract][Full Text] [Related]
33. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.
Quirt I; Robeson C; Lau CY; Kovacs M; Burdette-Radoux S; Dolan S; Tang SC; McKenzie M; Couture F;
J Clin Oncol; 2001 Nov; 19(21):4126-34. PubMed ID: 11689580
[TBL] [Abstract][Full Text] [Related]
34. Cancer anemia survey in Division of Medical Oncology at Siriraj Hospital (CAS).
Ithimakin S; Srimuninnimit V
J Med Assoc Thai; 2009 Mar; 92 Suppl 2():S110-8. PubMed ID: 19562994
[TBL] [Abstract][Full Text] [Related]
35. [Erythropoietic protein supportive treatment in small cell lung cancer].
Tamási L; Müller V; Magyar P; Losonczy G
Magy Onkol; 2008 Mar; 52(1):43-6. PubMed ID: 18403296
[TBL] [Abstract][Full Text] [Related]
36. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
37. Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: results from the Anemia Cancer Treatment (ACT) study.
Aapro M; Ludwig H; Bokemeyer C; MacDonald K; Soubeyran P; Turner M; Albrecht T; Abraham I
Ann Oncol; 2009 Oct; 20(10):1714-21. PubMed ID: 19570966
[TBL] [Abstract][Full Text] [Related]
38. Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients.
Durmaz O; Demirkaya M; Sevinir B
Pediatr Hematol Oncol; 2011 Sep; 28(6):461-8. PubMed ID: 21707225
[TBL] [Abstract][Full Text] [Related]
39. Use of darbepoetin alfa in European clinical practice for the management of chemotherapy-induced anaemia in four tumour types: final data from the CHOICE study.
Aerts JG; Swieboda-Sadlej A; Karanikiotis C; Labourey JL; Galid A; Wheeler T; Pujol B; Van Belle S
Curr Med Res Opin; 2012 Jul; 28(7):1089-99. PubMed ID: 22642866
[TBL] [Abstract][Full Text] [Related]
40. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Hamilton L; Bridges K; Pujol B
BMC Cancer; 2009 Sep; 9():311. PubMed ID: 19728887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
